In the present political environment, there is the potential that the majority of the population could be required to be vaccinated, even those demographics that were not vulnerable to the severe effects of COVID-19, and particularly those in the youngest demographic. The potential adverse consequences of such a mass inoculation with a vaccine not adequately tested for mid- and long-term adverse effects could be substantial.

5. Conclusions
The present assessment raises the question whether it would be necessary to rethink policies and use COVID-19 vaccines more sparingly and with some discretion only in those that are willing to accept the risk because they feel more at risk from the true infection than the mock infection. Perhaps it might be necessary to dampen the enthusiasm by sober facts? In our view, the EMA and national authorities should instigate a safety review into the safety database of COVID-19 vaccines and governments should carefully consider their policies in light of these data. Ideally, independent scientists should carry out thorough case reviews of the very severe cases, so that there can be evidence-based recommendations on who is likely to benefit from a SARS-CoV2 vaccination and who is in danger of suffering from side effects. Currently, our estimates show that we have to accept four fatal and 16 serious side effects per 100,000 vaccinations in order to save the lives of 2–11 individuals per 100,000 vaccinations, placing risks and benefits on the same order of magnitude.

Evidence in Favor of Casual Association between COVID-19 Vaccinations and Death
Although the evidence support that COVID-19 vaccines are safe, there are occasional instances where health authorities recognize that each of the authorized vaccines can cause side effects or establish a causal relationship between deaths. A plausible theoretical risk that is not unexpected exist.

Incidence of myocarditis after receiving mRNA vaccines are common [47]. On June 25, 2021, the FDA notified recipients and caregivers about the possibility of heart-related effects and further stated that the chance of having them is low [47]. They often happen in adolescents and young people, and symptoms of shortness of breath, chest pain, and fast-beating are to be observed [47]. The CDC and FDA briefly halted the distribution of the Janssen COVID-19 vaccine due to cases of thrombosis with thrombocytopenia syndrome (TTS). According to the CDC, the vaccine’s known and potential benefits outweigh its known and potential risk in individuals aged 18 years and above and TTS is low. The EMA prompted Janssen to provide warning labels for their vaccines. GBS was reported in some people following the administration of Johnson & Johnson vaccines [48].

Same with AstraZeneca, the EMA and Danish health authorities observed 30 reported cases of blood clots after vaccination of 5 million people [49]. Four European (Denmark, Germany, France, and Norway) countries then paused their distribution before resuming them as a precautionary response [50]. On the contrary and in a different setting, the Covishield locally manufactured version of the Oxford-AstraZeneca has not seen any incidence of blood clots in India. There are also other developed brands of the COVID-19 vaccines such as the CanSino and Gamaleya, Bharat Biotech, Sinopharm, Sinovac, CoviVac and QazCovid-in, and FBRI with no report of serious adverse effects.

Originally Posted By Azrairc⏩

Originally Posted By JIA⏩

Originally Posted By II

Originally Posted By umop3pisdn⏩

Originally Posted By OPGenesis⏩